The infarct size was significantly larger in homozygous ADAMTS-13-deficient mice (22.2 ± 1.1%), compared to heterozygous ADAMTS-13-deficient mice (17.3 ± 0.8%) and wild-type mice (16.9 ± 1.2%), which suggests that a level of approximately 50% of ADAMTS-13 in plasma is sufficient to prevent aggravated MI. Here, ADAMTS13 is linked to myocardial infarction.